Peripheral blood stem cells (PBSC) have recently been employed as a stem cell source in allogeneic transplantation, because PBSC transplantation achieved earlier neutrophil and platelet recovery than bone marrow transplantation (BMT). 1 However, a significant percentage of donors responded poorly to granulocyte colony-stimulating factor (G-CSF). Wiesneth et al 2 reported that a bone marrow (BM) harvest or the use of another stem cell donor was required in 4% of donors after G-CSF administration. Therefore, it is useful to be able to predict the total amount of harvested CD34 + cells before or soon after G-CSF administration. It has been reported previously that adhesion molecules play some role during mobilization from BM to peripheral blood (PB). 3 We also reported an inverse relation between CD11b expression and the total amount of harvested CD34 + cells harvested on fourth and fifth days during G-CSF administration. 4 Recently, Velders et al 5 reported that antibodies against alpha chains of beta2 integrins enhanced G-CSF-induced stem cell mobilization. We have also been studying CD11a and CD11b expression on PB CD34 + cells before G-CSF administration. After informed consent was obtained, 10 mg/kg/day (per donor body weight) of nartograstim (Kyowa Hakko Kogyo Co. Ltd, Tokyo, Japan) was administered by subcutaneous injection once a day to seven healthy sibling donors. The mean age of the two male and five female donors was 35.9 years, ranging from 21 to 56 years. PBSC apheresis was performed by a CS-3000-plus cell separator (Baxter, Fenwall Deerfield, IL, USA) on the fourth and fifth days during G-CSF administration. A volume of 8-10 l of donor PB was processed during each apheresis. The mean white blood cell (WBC) counts on the fourth and fifth days were 45.2 Â 10 9 /l (range: 38.4-53.0) and 48.5 Â 10 9 /l (range: 34.8-69.5), respectively. The body weight of donors ranged from 46 to 60 kg. Consequently, the apheresis volume per each donor body weight was ranged from 133.3 to 200 ml/ kg. It has been reported that larger volume leukaphereses produced more CD34 + cells. 6, 7 In practice, the total harvested CD34 + cell number is the most important factor for the safety of recipients other than percent concentration or fold increase of CD34 + cells in donor's PB. So, we chose the total amount of harvested CD34 + cells per donor body weight and processed blood volume (#hCD34 + ) as the measure of mobilization outcome. The #hCD34 + on the fourth and fifth days (mean7SD) were 5.8472.02 Â 10 (Figure 1(a) ) and with the MFI of CD11b expression on PB CD34 + cells (r ¼ À0.874, P ¼ 0.0069) (Figure 1(b) ).
Although only a small number of CD34 + cells and donors are included, the present study indicates a clear and significant correlation between #hCD34 + and the MFI of CD11a and CD11b expression on PB CD34
+ cells before G-CSF administration. Velders et al. 5 reported that administration of antibodies against the alpha chain of LFA-1 (CD11a) and/or against the alpha chain of Mac-1 (CD11b), followed by daily injections of G-CSF for more than 1 day, resulted in a significant enhancement of hematopoietic progenitor cell mobilization when compared with mobilization induced by G-CSF alone in mice. In our hands, donors with lesser CD11a and/or CD11b expression on PB CD34 + cells are in a similar state to those after administration of these antibodies, from whom more CD34 + cells are harvested. Thus, our results are compatible with those of Velders et al, thus suggesting the possibility of predicting the total amount of harvested CD34 + cells before G-CSF administration.
Concerning this change of CD11a and CD11b expression on PB CD34 + cells, biological roles are still to be clarified. We previously reported that the MFI of CD11b expression on CD34 + cells in PBSC bags harvested on the fourth and fifth days inversely correlated with #hCD34 + (r ¼ À0.639, P ¼ 0.0063) for 16 yields harvested on both the fourth and fifth days. In only eight yields harvested on the fifth day, a more significant reverse correlation (r ¼ À0.912, P ¼ 0.0006) was found. 4 The present study shows that the inverse correlation between #hCD34 + and MFI of CD11b expression before G-CSF injection is preserved on harvesting days. These results suggest that CD11b expression on CD34 + cells has some direct role in the mobilization from BM to PB. In contrast, we found in another study that the MFI of CD11a expression on CD34 + cells in PBSC bags harvested on the fourth and fifth days was not correlated with #hCD34 + (data not shown). This suggests that the inverse correlation between #hCD34 + and the MFI of CD11a expression before G-CSF injection was not preserved on harvesting days. These results suggest that the biological roles in the CD34 + cell mobilization process differed between CD11a and CD11b.
In conclusion, the present study indicates a clear and significant correlation between #hCD34 + and the MFI of CD11a and CD11b on CD34 + cells in steady-state PB, which suggests the possibility of predicting the amount of harvested CD34
+ cells before G-CSF administration. However, we only studied a small number of CD34 + cells and donors. Thus, further work is necessary to clarify the significance of the MFI of CD11a and CD11b expression on CD34 + cells in a steady state.
